Literature DB >> 16515839

Dose-related antiallodynic effects of cyclic AMP response element-binding protein-antisense oligonucleotide in the spared nerve injury model of neuropathic pain.

Y-Y Wang1, S-X Wu, L Zhou, J Huang, W Wang, X-Y Liu, Y-Q Li.   

Abstract

A transcription factor known as cyclic AMP response element-binding protein has been shown to be involved in the central sensitization in neuropathic pain and inflammation pain. The present study examined the roles of cyclic AMP response element-binding protein and of the phosphorylated cyclic AMP response element-binding protein in the maintenance of mechanical and cold allodynia induced by a neuropathic pain model, "spared nerve injury," in rats. First, the results of immunohistochemical study showed that phosphorylated cyclic AMP response element-binding protein, but not cyclic AMP response element-binding protein, increased bilaterally in the spinal dorsal horn 14 days following spared nerve injury, indicating a possible contribution of phosphorylated cyclic AMP response element-binding protein in spared nerve injury. Second, chronic intrathecal application of cyclic AMP response element-binding protein antisense oligodeoxynucleotide with three doses (10 microg/day, 20 microg/day and 40 microg/day) for 5 days demonstrated that the higher doses (20 and 40 microg) significantly attenuated both mechanical (bilaterally) and cold (ipsilaterally) allodynia, compared with sense oligodeoxynucleotide and the lower dose (10 microg). Western blot results showed that the alleviation in intensity of behavioral performance was accompanied by a significant reduction of total cyclic AMP response element-binding protein and phosphorylated cyclic AMP response element-binding protein in the spinal dorsal horn. Moreover, there were no differences in cyclic AMP response element-binding protein and phosphorylated cyclic AMP response element-binding protein between ipsilateral and contralateral dorsal horns. Our data demonstrate a close association between the expression of behavioral hypersensitivity and cyclic AMP response element-binding protein activation in the spinal dorsal horn following spared nerve injury, supporting the notion that phosphorylated cyclic AMP response element-binding protein may play an important role in the maintenance of chronic neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515839     DOI: 10.1016/j.neuroscience.2006.01.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  The cyclic AMP response element-binding protein antisense oligonucleotide induced anti-nociception and decreased the expression of KIF17 in spinal cord after peripheral nerve injury in mice.

Authors:  Jinhua Bo; Wei Zhang; Xiaofeng Sun; Yan Yang; Xiaojie Liu; Ming Jiang; Zhengliang Ma; Xiaoping Gu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain.

Authors:  Wei Wang; Wen Wang; Xiaopeng Mei; Jing Huang; Yanyan Wei; Yayun Wang; Shengxi Wu; Yunqing Li
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

3.  EXPRESS: Phospholipase C gamma mediates endogenous brain-derived neurotrophic factor - regulated calcitonin gene-related peptide expression in colitis - induced visceral pain.

Authors:  Fiza Hashmi; Miao Liu; Shanwei Shen; Li-Ya Qiao
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

4.  Crosstalk between Activated Microglia and Neurons in the Spinal Dorsal Horn Contributes to Stress-induced Hyperalgesia.

Authors:  Jian Qi; Chen Chen; Qing-Xi Meng; Yan Wu; Haitao Wu; Ting-Bao Zhao
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

5.  CREB-regulated transcription coactivator 1 enhances CREB-dependent gene expression in spinal cord to maintain the bone cancer pain in mice.

Authors:  Ying Liang; Yue Liu; Bailing Hou; Wei Zhang; Ming Liu; Yu-E Sun; Zhengliang Ma; Xiaoping Gu
Journal:  Mol Pain       Date:  2016-04-08       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.